Protection against H5N1 Highly Pathogenic Avian and Pandemic (H1N1) 2009 Influenza Virus Infection in Cynomolgus Monkeys by an Inactivated H5N1 Whole Particle Vaccine

H5N1 highly pathogenic avian influenza virus (HPAIV) infection has been reported in poultry and humans with expanding clade designations. Therefore, a vaccine that induces immunity against a broad spectrum of H5N1 viruses is preferable for pandemic preparedness. We established a second H5N1 vaccine candidate, A/duck/Hokkaido/Vac-3/2007 (Vac-3), in our virus library and examined the efficacy of inactivated whole particles of this strain against two clades of H5N1 HPAIV strains that caused severe morbidity in cynomolgus macaques. Virus propagation in vaccinated macaques infected with either of the H5N1 HPAIV strains was prevented compared with that in unvaccinated macaques. This vaccine also prevented propagation of a pandemic (H1N1) 2009 virus in macaques. In the vaccinated macaques, neutralization activity, which was mainly shown by anti-hemagglutinin antibody, against H5N1 HPAIVs in plasma was detected, but that against H1N1 virus was not detected. However, neuraminidase inhibition activity in plasma and T-lymphocyte responses in lymph nodes against H1N1 virus were detected. Therefore, cross-clade and heterosubtypic protective immunity in macaques consisted of humoral and cellular immunity induced by vaccination with Vac-3.

[1]  Y. Sakoda,et al.  Pathogenicity of Pandemic H1N1 Influenza A Virus in Immunocompromised Cynomolgus Macaques , 2013, PloS one.

[2]  M. Eichelberger,et al.  Molecular Basis for Broad Neuraminidase Immunity: Conserved Epitopes in Seasonal and Pandemic H1N1 as Well as H5N1 Influenza Viruses , 2013, Journal of Virology.

[3]  T. Honda,et al.  Potency of an inactivated influenza vaccine prepared from a non-pathogenic H5N1 virus against a challenge with antigenically drifted highly pathogenic avian influenza viruses in chickens. , 2013, Veterinary microbiology.

[4]  M. Peiris,et al.  Evaluation of In Vitro Cross-Reactivity to Avian H5N1 and Pandemic H1N1 2009 Influenza Following Prime Boost Regimens of Seasonal Influenza Vaccination in Healthy Human Subjects: A Randomised Trial , 2013, PloS one.

[5]  H. Inoko,et al.  Memory Immune Responses against Pandemic (H1N1) 2009 Influenza Virus Induced by a Whole Particle Vaccine in Cynomolgus Monkeys Carrying Mafa-A1*052∶02 , 2012, PloS one.

[6]  A. Takada,et al.  Reintroduction of H5N1 highly pathogenic avian influenza virus by migratory water birds, causing poultry outbreaks in the 2010-2011 winter season in Japan. , 2012, The Journal of general virology.

[7]  J. Oxford,et al.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans , 2012, Nature Medicine.

[8]  R. Donis,et al.  Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature , 2011, Influenza and other respiratory viruses.

[9]  N. Cox,et al.  Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets. , 2011, The Journal of infectious diseases.

[10]  M. Tashiro,et al.  Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice. , 2011, Vaccine.

[11]  R. Webby,et al.  A Contributing Role for Anti-Neuraminidase Antibodies on Immunity to Pandemic H1N1 2009 Influenza A Virus , 2011, PloS one.

[12]  K. Subbarao,et al.  Vesicular Stomatitis Virus-Based H5N1 Avian Influenza Vaccines Induce Potent Cross-Clade Neutralizing Antibodies in Rhesus Macaques , 2011, Journal of Virology.

[13]  H. Ehrlich,et al.  Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. , 2010, Vaccine.

[14]  Xiufan Liu,et al.  Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine. , 2010, Veterinary microbiology.

[15]  Yukiko Muramoto,et al.  Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans between 2003 and 2008 in northern Vietnam , 2010, The Journal of general virology.

[16]  Ryo Takano,et al.  Influenza A (H5N1) Viruses from Pigs, Indonesia , 2010, Emerging infectious diseases.

[17]  A. Takada,et al.  Antigenic, genetic, and pathogenic characterization of H5N1 highly pathogenic avian influenza viruses isolated from dead whooper swans (Cygnus cygnus) found in northern Japan in 2008 , 2010, Virus genes.

[18]  Noriko Kishida,et al.  Molecular Evolutionary Analysis of the Influenza A(H1N1)pdm, May–September, 2009: Temporal and Spatial Spreading Profile of the Viruses in Japan , 2010, PloS one.

[19]  Y. Sakoda,et al.  Subcutaneous inoculation of a whole virus particle vaccine prepared from a non-pathogenic virus library induces protective immunity against H7N7 highly pathogenic avian influenza virus in cynomolgus macaques. , 2010, Vaccine.

[20]  三宅 太一郎.  Amelioration of pneumonia with Streptococcus pneumoniae infection by inoculation with a vaccine against highly pathogenic avian influenza virus in a non-human primate mixed infection model , 2010 .

[21]  Hideo Goto,et al.  In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses , 2009, Nature.

[22]  Gabriele Neumann,et al.  Emergence and pandemic potential of swine-origin H1N1 influenza virus , 2009, Nature.

[23]  Carole R. Baskin,et al.  Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus , 2009, Proceedings of the National Academy of Sciences.

[24]  M. Kiso,et al.  Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. , 2008, Vaccine.

[25]  H. Ehrlich,et al.  A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. , 2008, The New England journal of medicine.

[26]  Y. Sakoda,et al.  Development of vaccine strains of H5 and H7 influenza viruses. , 2008, The Japanese journal of veterinary research.

[27]  Y. Kawaoka,et al.  A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. , 2008, Vaccine.

[28]  A. Osterhaus,et al.  Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine , 2008, PloS one.

[29]  Y. Sakoda,et al.  Library of influenza virus strains for vaccine and diagnostic use against highly pathogenic avian influenza and human pandemics. , 2006, Developments in biologicals.

[30]  T. Kurata,et al.  Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. , 2005, Japanese journal of infectious diseases.

[31]  R. Webster,et al.  Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus , 2005, Archives of Virology.

[32]  T. Gojobori,et al.  Molecular evolution of hemagglutinin genes of H1N1 swine and human influenza A viruses , 2005, Journal of Molecular Evolution.

[33]  Constance Schultsz,et al.  Avian influenza A (H5N1) in 10 patients in Vietnam. , 2004, The New England journal of medicine.

[34]  K. Hayashi,et al.  Rabbit model for human EBV-associated hemophagocytic syndrome (HPS): sequential autopsy analysis and characterization of IL-2-dependent cell lines established from herpesvirus papio-induced fatal rabbit lymphoproliferative diseases with HPS. , 2003, The American journal of pathology.

[35]  J. Mcghee,et al.  Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. , 2001, The Journal of infectious diseases.

[36]  P. Doherty,et al.  CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. , 1997, Journal of immunology.

[37]  H. Kida,et al.  Molecular evidence for a role of domestic ducks in the introduction of avian H3 influenza viruses to pigs in southern China, where the A/Hong Kong/68 (H3N2) strain emerged. , 1991, The Journal of general virology.

[38]  H. Ishiko,et al.  Establishment of a B‐Lymphoblastoid Cell Line Infected with Epstein‐Barr‐Related Virus From a Cynomolgus Monkey (Macaca fascicularis) , 1990, Journal of medical primatology.

[39]  R. Webster,et al.  Origin of the hemagglutinin gene of H3N2 influenza viruses from pigs in China. , 1988, Virology.

[40]  C. Naeve,et al.  Antigenic and genetic conservation of H3 influenza virus in wild ducks. , 1987, Virology.

[41]  R B Couch,et al.  Immunity to influenza in man. , 1983, Annual review of microbiology.

[42]  A. McMichael,et al.  Cytotoxic T-cell immunity to influenza. , 1983, The New England journal of medicine.

[43]  J. Virelizier,et al.  Host defenses against influenza virus: the role of anti-hemagglutinin antibody. , 1975, Journal of immunology.